Wire · opportunities
Analysis-Hims & Hers stands to gain if the FDA loosens restrictions on peptides
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
The FDA advisory committee is meeting this week to consider loosening compounding restrictions on seven peptides, a move that could unlock a $2.2–3.3 billion market. Hims & Hers, which acquired peptide manufacturing capability in 2025, stands to be a major beneficiary if regulations ease, though final rulemaking could take up to a year.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 23 Jul 2026 and 25 Jul 2026.
◆ ◆ The Wire takeaway
If the FDA loosens peptide compounding rules this week, Hims has already paid for the factory and the supply chain. Your window to build a compounding pharmacy or peptide sourcing business is closing—the money is moving to execution, not permission.
◆ Coverage
2 sources · first reported 23 Jul 2026 · latest 25 Jul 2026
◆ Related on Wire
◆ Topics